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for 1.1% of male years of life lost and 1.4% of female years of
life lost in the same year.3 This high morbidity and unnecessary
mortality occurred despite readily available and cost-effective
treatment regimens. The aim of clinical guidelines is to
promote good medical practice4 by assisting practitioners to
provide optimal and cost-effective care. Eccles et al.5 in the
former Northern Region of the UK, found that 25% of practices
were not aware of the availability of guidelines for the
management of asthma, diabetes and hypertension.5 Studies
have found that even when clinical guidelines are available
they are not adopted. It is therefore imperative that a strategy
promoting the acceptance and use of clinical guidelines by
practitioners be developed.6 By using asthma guidelines, the
severity of asthma is more likely to be graded accurately and
medicated appropriately. To encourage adherence to the
prescribed regimen it is important for practitioners to ensure
that patients understand the necessity for and the safety of
inhaled steroids. The use of cough mixtures is neither
recommended nor indicated in the management of asthma.
The finding in this study that 36.4% of patients did not
receive the recommended medication commensurate with the
severity of their asthma is cause for concern. If this problem is
not addressed, it is unlikely that there will be an improvement
in the current unacceptably high morbidity and mortality
associated with asthma in South Africa.
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A phosphodiesterase inhibitor promotes the premature
development of adverse cardiac remodelling mediated 
by beta-adrenergic activation in hypertension
To the Editor: Cardiac dilatation is thought to contribute to
pump dysfunction in heart failure. In hypertension, left
ventricular hypertrophy (LVH) can progress from a concentric
geometry to left ventricular (LV) dilatation. The mechanisms
responsible for the transition from concentric LVH to cardiac
dilatation in hypertension are uncertain. In human studies LVH
is associated with an increased sympathetic activity to the
myocardium, but not to other tissue beds.1 Our group has
therefore proposed that sympathetic over-activation in LVH
could mediate the transition from concentric LVH to cardiac
dilatation. Indeed, we have demonstrated that in
spontaneously hypertensive rats (SHRs) with concentric LVH,
daily administration of low doses of a beta-adrenoreceptor 
(β-AR) agonist promotes the development of marked cardiac
dilatation.2 However, β-AR-induced effects can be mediated by
cyclic adenosine monophosphate (cAMP)-dependent and
independent pathways.3 To explore the role of β-AR-cAMP
pathways in mediating the transition from concentric LVH to
LV dilatation, we evaluated the effect of a phosphodiesterase
inhibitor (PDEI), used either alone or with a β-AR agonist, on
LV geometry and function in SHRs with concentric LVH.
Methods
Fourteen-month-old SHRs and Wistar Kyoto (WKY) control
rats were used for this study. SHRs either received no therapy,
a β-AR agonist (isoproterenol, daily as previously described2), a
PDEI (pentoxifylline, 50 mg/kg/day in the drinking water), or
both the β-AR agonist and the PDEI for 3 months. To ensure
that the β-AR agonist was effective, additional SHRs were either
left untreated or received the β-AR agonist for 5.5 months.
LV cavity size was assessed using three techniques. First,
two-dimensional directed M-mode echocardiography was
performed using a Sonos model 2500 Hewlett Packard
echocardiograph with a 7.5 MHz transducer.4 Second, LV end
diastolic (LVED) dimensions were assessed using piezoelectric
ultrasonic transducers placed across the short axis of the heart
at controlled LVED pressures (LVEDP) in open-chest,
ventilated rats.2 Third, LV diastolic pressure-volume relations
were constructed in isolated, perfused heart preparations and
the volume intercept at a diastolic pressure of  0 mmHg 
(LV V0) was determined.
2,4 To assess further the impact of the
β-AR agonist and the PDEI on cardiac remodelling, myocardial
collagen content was determined using hydroxyproline
((HPRO) determinations.2,4
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Results
LV cavity dimensions were similar between WKY rats (data not
shown) and untreated SHRs (Table I). Although the β-AR
agonist was able to induce significant cardiac dilatation after
5.5 months of administration to SHRs (data not shown), 3
months of administration of the β-AR agonist to SHRs failed to
induce LV dilatation (Table I). Further, although administration
of the PDEI alone failed to modify LV parameters (data not
shown), co-administration of the β-AR agonist and the PDEI to
SHRs produced marked increases in LV cavity dimensions and
myocardial collagen concentrations (Table I).
Discussion
The main findings of this study are that a PDEI potentiates 
β-AR agonist-mediated LV dilatation in SHRs with concentric
LVH. As PDEIs and β-AR agonists share a common cellular
pathway, namely the β-AR-cAMP pathway, these data suggest
that cAMP is an important mediator of the transition from
concentric LVH to LV dilatation. The clinical implication of
these findings is that pharmacological agents that increase the
activity of this pathway could promote further dilatation in
LVH in heart failure.
These findings were presented at the 13th Biennial Congress
of the South African Hypertension Society, Johannesburg, 7 - 9
March 2003.
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Table I. Effect of chronic administration of the phosphodiesterase
inhibitor (PDEI), pentoxifylline, on left ventricular (LV)
dimensions and myocardial collagen characteristics in
spontaneously hypertensive rats (SHRs) (mean ± SEM)
SHR groups
β-AR agonist +
Treatment Placebo β-AR agonist PDEI
Sample size (N) 8 7 9
LVEDD (cm) 0.67 ± 0.02 0.65 ± 0.03 0.75 ± 0.03*
LVEDr† (cm) 0.25 ± 0.04 0.31 ± 0.04 0.37 ± 0.03*
LV V0 (ml) 0.20 ± 0.01 0.22 ± 0.01 0.27 ± 0.01*
HPRO‡ 5.6 ± 0.6 6.4 ± 0.9 8.5 ± 0.8*
*p < 0.05 versus placebo treated.
†At an LVED pressure of 2 mmHg.
‡In µg/mg dry LV.  
β-AR = beta-adrenoreceptor; PDEI = phosphodiesterase inhibitor; LVEDD = left
ventricular end diastolic diameter; LVEDr = left ventricular end diastolic radius; 
LV V0 = volume intercept at a left ventricular diastolic pressure of 0 mmHg; HPRO =
hydroxyproline.
